E-LIB Suche - Ergebnisse für: Hutchings, M.

1

A RCT to explore the effectiveness of supporting adherence ..:

Bradley, J. M. ; Hutchings, M. ; Arden, M. A....
BMC Pulmonary Medicine. 24 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

2

Glofitamab plus immunochemotherapy demonstrates durable eff..:

Townsend, W. ; Topp, M. S. ; Dickinson, M....
Hematological Oncology. 41 (2023) S2 - p. 595-597 , 2023

Link: https://doi.org/10.1002/..

3

P147 "What options are available for those not able to take..:

Daniels, T. ; Lai, L.Y. ; Cameron, S....
Journal of Cystic Fibrosis. 22 (2023) - p. S110 , 2023

Link: https://doi.org/10.1016/..

4

P378 The value of a community of practice, within the CFHea..:

Daniels, T. ; Hutchings, M. ; Dawson, S....
Journal of Cystic Fibrosis. 22 (2023) - p. S179-S180 , 2023

Link: https://doi.org/10.1016/..

5

Evaluation of ctDNA in a phase I/II trial in relapsed or re..:

Soong, D. ; Thieblemont, C. ; Karavitis, J....
Hematological Oncology. 41 (2023) S2 - p. 326-328 , 2023

Link: https://doi.org/10.1002/..

6

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology. 41 (2023) S2 - p. 144-146 , 2023

Link: https://doi.org/10.1002/..

7

The experiences and needs of unpaid family caregivers for p..:

Campbell-Enns, Heather J. ; Bornstein, Stephen ; Hutchings, Veronica M. M....
PLOS ONE. 18 (2023) 6 - p. e0286548 , 2023

Link: https://doi.org/10.1371/..

8

GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS ..:

Carlo‐Stella, C. ; Hutchings, M. ; Offner, F....
Hematological Oncology. 41 (2023) S2 - p. 63-65 , 2023

Link: https://doi.org/10.1002/..

9

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:

Hutchings, M. ; Dickinson, M. ; Carlo‐Stella, C....
Hematological Oncology. 41 (2023) S2 - p. 136-138 , 2023

Link: https://doi.org/10.1002/..

10

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RE..:

Hutchings, M. ; Avigdor, A. ; Sureda, A....
Hematological Oncology. 41 (2023) S2 - p. 138-140 , 2023

Link: https://doi.org/10.1002/..

11

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REM..:

Thieblemont, C. ; Karimi, Y. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 142-144 , 2023

Link: https://doi.org/10.1002/..

12

P220 The CFHealthHub Learning Health System - supporting a ..:

Sandler, R.D. ; Antrobus, S. ; Cameron, S....
Journal of Cystic Fibrosis. 22 (2023) - p. S132 , 2023

Link: https://doi.org/10.1016/..

13

Enhanced ctDNA Profiling Reveals Molecular Determinants of ..:

Meriranta, L. ; Kolstad, A. ; Hutchings, M....
Hematological Oncology. 41 (2023) S2 - p. 477-478 , 2023

Link: https://doi.org/10.1002/..

14

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DUR..:

Belada, D. ; Falchi, L. ; Leppä, S....
Hematological Oncology. 41 (2023) S2 - p. 125-127 , 2023

Link: https://doi.org/10.1002/..

15

P207 CFHealthHub allows clinicians to identify people with ..:

Sandler, R.D. ; Lai, L. ; Anderson, A....
Journal of Cystic Fibrosis. 22 (2023) - p. S128 , 2023

Link: https://doi.org/10.1016/..